German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl.

Inclusion Criteria: * Males and females, 16 to 74 years, diagnosed with Fabry disease. * Amenable GLA mutation. * Treatment with Migalastat (initiation of therapy according to recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Biegstraaten et al, Orphanet J Rare Dis. 2015;10:36. AWMF-Leitlinien Morbus Fabry, Diagnose und Therapie, Registernummer 030-134). The following Inclusion criteria refer to the time of Migalastat initiation (T0): * ERT naïve (patients with signs of organ involvement (kidney, heart and/or CNS signs) to be considered for ERT following the European Consensus Guidelines on ERT (Biegstraaten et al 2015) or patients with neuropathic pain not controlled with pain medication or patients with GI symptoms not relieved with standard medication or ERT switch patients (under ERT for ≥12 months). * Estimated GFR (eGFR, CKD-EPI formula) at screening ≥30 ml/min/1.73 m2 * Subjects taking no ACE inhibitors, ARBs, or renin inhibitors or are on a stable dose for at least 4 weeks before screening. * Subjects taking no analgesics/antidepressants or are on a stable dose for at least 4 weeks before screening. Exclusion Criteria: * Patient has a non-amenable GLA mutation or the mutation A143T or D313Y (for verification of amenable mutations please refer to: www.GalafoldAmenablityTable.com or to the "Fachinformation"). * Patient is unwilling to give informed consent. * Patient is unable to comply with the clinical protocol. * Patients on co-medication: Galafold plus Enzyme Replacement Therapy (ERT) * Pregnant or breast feeding women. The following Exclusion criteria refer to the time of Migalastat initiation (T0): * Patients on dialysis * Patient has a clinically significant organ disease (e.g. cancer in the past 5 years) that in the opinion of the investigator would preclude participation in the trial. * Patients with a history of organ transplantation.